Anne Floquet - Concepedia

Author

Anne Floquet

Also Known As

A Floquet, A. FLOQUET, A. Floquet, ANNE FLOQUET, Anne Floquet, F. Fiteni, Floquet A, Floquet, A, Laure Favier, Michel Fabbro

496

Publications

17.9K

Citations

H-Index

Concepts

All Affiliations

Institut Bergonié Institut Gustave Roussy Centre Léon Bérard Institut Curie Institut Claudius Regaud

About

Anne Floquet is an author at Institut Bergonié specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	54	9.6K
2	Health Sciences	9	9	848
3	Public Health	2	2	177
4	Engineering	1	1	68
5	Natural Sciences	1	1	50

Anne Floquet

105

Publications

14.9K

Citations

H-Index

Page 1

	Year	Citations
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, New England Journal of Medicine	2018	2.7K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, The Lancet Oncology MedicinePharmacologyPathologyCancer TreatmentOncology	2016	1.2K
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up L. Mauriac, Gaëtan MacGrogan, A. Avril, Annals of Oncology Surgical OncologyOncologyNeoadjuvant ChemotherapyBreast Oncology124-Month Median Follow-up	1999	440
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Journal of Clinical Oncology	2022	432
Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson, Journal of Clinical Oncology	2012	424
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Cancer Discovery	2017	396
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer Andreas du Bois, Anne Floquet, Jae‐Weon Kim, Journal of Clinical Oncology	2014	318

Page 1